Oxford, UK – 3 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin® for the treatment of Parkinson’s disease (PD) will be presented on Saturday 21 May, 2011 at the American Society of Gene & Cell Therapy (ASGCT) 14th Annual Meeting in Seattle, USA by the study’s Principal Investigator, Professor Stéphane Palfi of the Henri Mondor Hospital in Paris.
The third patient cohort consists of three patients treated with a 2x dose of ProSavin®using an enhanced administration method. The top-line results at six months, which have been independently validated, are:
1. Motor function is assessed according to the Unified Parkinson’s Disease Rating Scale (UPDRS) in patients’ “OFF” state (i.e. after withdrawal of PD medication).
Summary of improvements in motor function to date2:
2. Historical data has been independently verified.
John Dawson, Chief Executive Officer of Oxford BioMedica, said: “With an average motor function improvement of 43%, these are the highest efficacy results we have reported for our ProSavin® Phase I/II programme to date. Subject to advice from the study’s Data Monitoring Committee and regulatory bodies, we believe the current data set already supports advancing ProSavin® into sham-controlled studies at the earliest opportunity. If these results are confirmed in randomised studies, ProSavin® has the potential to significantly improve the treatment paradigm for Parkinson’s disease patients globally. We look forward to the presentation of the full data set at the ASGCT and, with results from the higher 5x dose cohort expected in H2 2011, remain confident that the strength of these data will help to derive maximum value from our partnering discussions.”
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700
Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900
WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321